Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical TrialPlain-Language Summary

Rationale & Objective: In kidney transplant recipients (KTRs), a belatacept-based immunosuppressive regimen is associated with beneficial effects on cardiovascular (CV) risk factors compared with calcineurin inhibitor (CNI)–based regimens. Our objective was to compare the calculated CV risk betw...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Obbo W. Bredewold, MD, Joe Chan, My Svensson, Annette Bruchfeld, Johan W. de Fijter, Hans Furuland, Josep M. Grinyo, Anders Hartmann, Hallvard Holdaas, Olof Hellberg, Alan Jardine, Lars Mjörnstedt, Karin Skov, Knut T. Smerud, Inga Soveri, Søren S. Sørensen, Anton-Jan van Zonneveld, Bengt Fellström
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2023-01-01
coleção:	Kidney Medicine
Assuntos:	Kidney transplantation randomized clinical trial belatacept calcineurin inhibitors tacrolimus cardiovascular disease
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2590059522002072
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!